7Baggers
 Scynexis fungerps among funding recipients  BioWorld MedTech Tue, 18 Nov 2025 13:00:00 GMT
 SCYX Secures Federal Grant for Antifungal Research  GuruFocus Mon, 17 Nov 2025 16:10:55 GMT
 Barratt Redrow Advances Share Repurchase Program with Latest Buyback  The Globe and Mail Sun, 09 Nov 2025 11:35:02 GMT
 Scynexis at a Crossroads: Can a GSK Deal Reverse Its Fortunes?  Ad-hoc-news.de Sat, 08 Nov 2025 13:03:03 GMT
 ubs sticks to its hold rating for westpac banking (webnf)  The Globe and Mail Fri, 07 Nov 2025 18:07:53 GMT
 scynexis lands major payout and eyes a turnaround  Finimize Fri, 07 Nov 2025 04:19:08 GMT
 Acute Vulvovaginal Candidiasis Treatment Market To Witness  openPR.com Thu, 06 Nov 2025 10:27:04 GMT
 Scynexis Lands Major Payout And Eyes A Turnaround  Finimize Thu, 06 Nov 2025 08:54:16 GMT
 scynexis: q3 earnings snapshot  Chron Thu, 06 Nov 2025 00:47:36 GMT
 scynexis reports q3 eps (17c), consensus (20c)  TipRanks Thu, 06 Nov 2025 00:24:10 GMT
 scyx achieves key milestones and exceeds q3 revenue expectations  GuruFocus Wed, 05 Nov 2025 23:57:52 GMT
 Antifungal drug developer Scynexis's Q3 net loss widens  TradingView Wed, 05 Nov 2025 22:53:55 GMT
 Scynexis: Q3 Earnings Snapshot  San Francisco Chronicle Wed, 05 Nov 2025 08:00:00 GMT

SCYNEXIS, Inc
(NASDAQ:SCYX) 

SCYX stock logo

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, i...

Full Time Employees: 27
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic

Share this website to your friends